Wafik S. El-Deiry was re-elected as the chair of the WIN Consortium in Precision Oncology.
The American Association for Cancer Research’s Project GENIE (Genomics Evidence Neoplasia Information Exchange), the world’s largest publicly accessible cancer registry of real-world clinico-genomic data, was selected as a winner of the 2025 Amazon Web Services Imagine Grant.Â
Robin Toft was appointed CEO of Curebound, a philanthropic organization that fundraises for and invests in cancer research, effective Jan. 1.Â
Curebound has announced eight grants for a total of $2 million in funding. The funding is made available through two new Curebound programs: Catalyst Grants, which support projects within early-stage life science companies that are seeking to take innovative discoveries to commercially approved products, and Equity Grants, which focus on overcoming disparities in cancer research and treatment in underserved populations.
Researchers have presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Group and Caris Life Sciences focused on transforming recurrence risk assessment in early-stage breast cancer through artificial intelligence.
The American Cancer Society is introducing two key changes for cervical cancer screening guidelines.Â
A Mayo Clinic study published in the New England Journal of Medicine demonstrates that an off-the-shelf, dual-antibody therapy can generate deep and durable responses in extramedullary multiple myeloma—one of the most aggressive and treatment-resistant forms of the disease.Â
Phase III STELLAR clinical study results have demonstrated that the combination of eflornithine and lomustine achieved clinically meaningful improvements in overall survival and progression-free survival compared to lomustine alone in patients with recurrent IDH mutant, grade 3 astrocytoma.Â
Mental health conditions are common among veterans and may play a larger role than previously recognized in raising liver cancer risk for those with hepatitis C.
Researchers at the LSU LCMC Health Cancer Center examined tumors from more than 250 Black and white women across Louisiana and uncovered key immune differences in patients with triple-negative breast cancer, one of the most aggressive forms of breast cancer.
